As we approach 2024, the Pharma industry’s focus on developing and maintaining meaningful relationships with healthcare professionals (HCPs) will only intensify.
In this ever-changing landscape, companies are re-embracing F2F strategies and adding virtual and hybrid options to enhance stakeholder experience while adhering to strict regulatory guidelines. The need to find more effective ways to connect with HCPs has never been more crucial.
In 2024, the pharmaceutical industry will prioritize gaining a deeper understanding of HCPs’ needs and behaviours. A recent study by EPG Health highlighted this trend (1), with approximately 60% of pharmaceutical respondents, indicating that HCP insight is a top priority for strategic HCP engagement.
Medical Science Liaisons remain in the lead
Medical science liaisons will continue to play a crucial role in delivering news and updates to healthcare professionals (HCPs), as well as gathering vital information and feedback on establishing and managing the relationship. HCPs value face-to-face or virtual interactions (1) with like-minded MSLs who understand and can discuss the science and data being shared, as well as provide medical, market, and business knowledge and information.
Need for deeper listening
Enhancing patient experience
The pharmaceutical industry is increasingly leveraging digital solutions and virtual care to enhance the patient experience. Patients now expect to be more actively involved in their healthcare journey. By creating direct-to-customer (DTC) digital experiences and solutions, pharmaceutical companies can strengthen their relationships with patients.
Role of wearables and digital health tracking tools